TipRanks
Go Ultimate55% OFF

Veeva Systems (VEE) AI Stock Analysis

DE:VEE

Veeva Systems

(XETRA:VEE)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Strong ProfitabilityVeeva’s high gross, operating, and net margins demonstrate a scalable cloud-software model with substantial earnings power. These margins can support continued product investment, customer support, and innovation while providing resilience if growth remains more moderate over the next several quarters.
Negative Factors
Revenue Growth DecelerationThe sharp slowdown in revenue growth suggests Veeva is becoming a more mature business and faces a tougher path to re-acceleration. Slower expansion can reduce operating leverage, limit the pace of market-share gains, and make future performance more dependent on successful new-product adoption.

Veeva Systems (VEE) vs. iShares MSCI Germany ETF (EWG)

-50%-40%-30%-20%-10%0%10%20%DE:VEE+10.13%EWG+4.43%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Market Cap
EUR 50.67B
Dividend Yield
―
Average Volume (3M)
136
Price to Earnings (P/E)
50.4
Beta (1Y)
0.81
Revenue Growth
9.55%
EPS Growth
17.09%
Country
Germany
Employees
7,928
Sector
Healthcare
Sector Strength
51
Industry
Software - Application

Veeva Systems Business Overview & Revenue Model

Company Description

Veeva Systems Inc. is a leading provider of cloud-based software solutions, exclusively dedicated to the global life sciences industry. Its extensive operational presence spans across North America, Europe, the Asia Pacific region, the Middle East, A...

Veeva Systems Earnings Call Summary

Earnings Call Date:Aug 25, 2026(Q2-2027)|% Change Since:32.28%|Next Earnings Date:Nov 25, 2026
Earnings Call SentimentPositive

The call communicated a predominantly positive operational and financial performance: revenue of $928M, non-GAAP operating income of $416M (~44.8% margin), strong commercial subscription growth (~13% YoY), record CRM results, and meaningful early traction in AI (Falcon) and Data Cloud. Management raised guidance and highlighted selective, disciplined investments (Aspen) and a healthy IQVIA partnership. Key risks centered on execution and timing for agentic AI (product readiness, onboarding capacity, pricing models), potential model-compute cost pressure, and staggered timing of R&D product ramps. Overall, highlights (strong revenue/profitability, CRM wins, AI interest, Data Cloud additions, guidance raise) materially outweigh the manageable near-term execution and timing lowlights.

Positive Updates

Strong Quarter — Revenue and Profitability
Total revenue of $928 million and non-GAAP operating income of $416 million in Q2 FY2027, implying a non-GAAP operating margin of ~44.8%, with results coming in ahead of guidance.

Negative Updates

Falcon — Early-Stage Risks and Capacity Constraints
Falcon is promising but early: Veeva describes itself as the 'rate limiter' — constrained product readiness and onboarding capacity for early adopters could limit near-term monetization and require careful execution of human-in-loop, training and regulatory guardrails.

Company Guidance

Management said it has raised and updated FY‑2027 guidance (with no material incremental investments for the fiscal year beyond what is already factored in), while reporting Q2 results of $928 million total revenue and $416 million non‑GAAP operating income; Commercial subscriptions were up about 13% year‑over‑year (double‑digit ex‑Crossix), Crossix remains a strong performer, Data Cloud added 14 customers, and Veeva has over 180 CRM customers live. They noted five Falcon early adopters with first go‑lives expected this year, described Aspen as a small, 90‑day‑paced investment not yet included in revenue plans, and said they will scale sales/R&D spend with revenue and revisit guidance for the next fiscal year after a few more quarters (while watching CRM win‑backs and product rollouts into 2027–2029).

Veeva Systems Risk Analysis

Veeva Systems disclosed 43 risk factors in its most recent earnings report. Veeva Systems reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Veeva Systems Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:VEE against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
PTCPTC87Outperform$21.24B18.8432.64%―19.50%143.45%
ROPROP83Outperform$46.15B18.4413.53%0.78%9.24%73.95%
DOCUDOCU77Outperform$15.36B49.2017.74%―8.59%20.88%
TEAMTEAM72Outperform$48.29B-912.95-4.39%―26.02%81.08%
WKWK69Neutral$4.55B100.73-123.75%―19.67%―
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

-60%-40%-20%0%20%DE:VEEROPPTCWKTEAMDOCUDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
DE:VEE and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:VEEVeeva Systems Inc279.5028.1011.18%
ROPRoper Technologies466.6022.355.03%
PTCPTC Inc.195.54-0.82-0.42%
WKWorkiva Inc.83.61-1.22-1.44%
TEAMAtlassian Corporation Plc191.7215.648.88%
DOCUDocusign82.179.1312.50%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.